Shots: Ultragenyx to receive $200m up front including $125M in cash & $75M equity investment at $60/share, $25M on completion of technology transfer the HeLa PCL and HEK293 platforms along […]readmore
Tags : Non-Exclusive
Shots: Glenmark to receive up front, license fee and royalties on sales and is responsible to manufacture and supply Remogliflozin. Torrent to get rights to commercialize Remogliflozin under the trademark […]readmore
Shots: Novartis will provide TNO155 at no cost while Mirati will sponsor the clinical study evaluating the combination therapy for solid tumors harboring KRAS G12C mutations and the companies will […]readmore
Shots: Synaffix to receive upfront and milestones leading to total deal value $125M and royalties on sales of product. Miracogen to get non-exclusive license rights for Synaffix’s GlycoConnect and HydraSpace […]readmore
Shots: Abbott to get non-exclusive license rights for Banyan’s TBI biomarkers, including Ubiquitin Carboxy-terminal Hydrolase-L1 (UCH-L1) and Glial Fibrillary Acidic Protein (GFAP) kit to utilize it on its laboratory instruments […]readmore
Shots: The companies entered into an agreement to assess insulin dose data from Novo Nordisk’ pre-filled insulin pen connected to the digital health tool marked with Abbott’s FreeStyle Libre system […]readmore
Shots: Pfizer to get worldwide IPR for Humira in the US and other countries and will pay royalties on sales to AbbVie Humira’s the US license right will begin from […]readmore